<SEC-DOCUMENT>0001193125-14-220277.txt : 20140623
<SEC-HEADER>0001193125-14-220277.hdr.sgml : 20140623
<ACCEPTANCE-DATETIME>20140530184009
ACCESSION NUMBER:		0001193125-14-220277
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140530
FILED AS OF DATE:		20140602
DATE AS OF CHANGE:		20140530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		14881768

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d734465d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated May 30, 2014 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Translation of Registrant&#146;s Name) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Level 7, 151 Macquarie Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sydney, 2000 New South Wales, Australia
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form <FONT
STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May 30, 2014 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima BioMed Ltd</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Matthew Lehman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Matthew Lehman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:75pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima&#146;s CVac Patent Application Receives U.S. Notice of Allowance</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d734465dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g734465ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>30&nbsp;May 2014 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED TO HOST
CONFERENCE CALL TO DISCUSS ABSTRACT PRESENTED AT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASCO ON NEW INTERIM OVERALL SURVIVAL AND FINAL PROGRESSION FREE SURVIVAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATA FOR THE COMPANY&#146;S CAN-003 TRIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Webcast to Include Dr.&nbsp;Heidi Gray, Lead Investigator, and Dr.&nbsp;Brad Monk, Chair of Prima&#146;s Clinical Advisory Board. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;, &#147;the Company&#148;) today advised that the Company will host a
conference call and webcast covering Dr.&nbsp;Heidi Gray&#146;s oral presentation at the American Society of Clinical Oncology (&#147;ASCO&#148;) to be given on May&nbsp;31, 2014 in Chicago, IL. The call and webcast will include discussions from
both Dr.&nbsp;Gray and Dr.&nbsp;Monk on data presented at ASCO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As earlier announced, the final CAN-003 progression free survival data and interim
overall survival data was accepted for oral presentation by Dr.&nbsp;Heidi Gray at ASCO&#146;s 2014 Annual Meeting. ASCO abstract #5504 entitled &#147;Progression-free survival in ovarian cancer patients in second remission is improved with mucin
1-autologous dendritic cell therapy&#148; is available at <U>http://abstracts.asco.org/</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast and Conference Call Details: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The call is scheduled for Tuesday, June&nbsp;3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> at 11am (Sydney local time). This corresponds to Monday,
June&nbsp;2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> at 9pm U.S. Eastern daylight time. The conference call dial-in numbers are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant Numbers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Australia Toll Free</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">1800 606 599</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Australia Local</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">+61 2 9007 8047</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Canada/USA</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">1 855 237 2970</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Germany</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">0800 189 9369</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The call will also be audio webcast with additional supplemental slides available via
<U>http://www.media-server.com/m/go/primabiomed-june-2014</U>. Before launching the webcast, it is recommended to click on the link and then on &#147;test your system configuration.&#148; A replay of the webcast will be available through
Prima&#146;s website following the live event. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the CAN-003 Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an observational standard of care arm (OSC), in epithelial ovarian cancer
patients in complete remission after first or second line treatment. In accordance with the protocol design, the first seven patients on the trial were all assigned to receive CVac in order to test the comparability of product manufacturing in a new
facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subsequent 56 patients were randomized 1:1 to either the CVac group or observational standard of care (OSC) and included in the
intent-to-treat analysis. 36 patients were in first remission (19 patients were assigned to CVac and 17 to OSC) and 20 patients were in second remission (10 patients were each assigned to CVac or OSC). Final PFS data was analysed after thorough
quality control reviews of investigator-evaluated progression and appropriate censoring of data from patients who had not progressed during the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objectives of the trial are to determine the safety of CVac administration and to determine CVac&#146;s effect on progression-free survival.
Secondary objectives of the trial are to determine CVac&#146;s effect of overall survival and to evaluate host immunologic responses to Cvac. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of
cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima&#146;s lead product is CVac&#153;, an autologous dendritic cell- based
product currently in clinical trials. <U>www.primabiomed.com.au</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USA Investor/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Holdsworth, ProActive Capital
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;862 4607; adamh@proactivecapital.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755; mgregorowski@citadelpr.com.au </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe Investor/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Axel M&uuml;hlhaus,
edicto GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69 905505-52; amuehlhaus@edicto.de </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au &nbsp;&nbsp;&nbsp;&nbsp;ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g734465ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g734465ex99_1pg01.jpg
M_]C_X``02D9)1@`!`0$`R`#(``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``P("0H)!PP*
M"0H-#`P.$1T3$1`0$2,9&Q4=*B4L*RDE*"@N-$(X+C$_,B@H.DXZ/T1'2DM*
M+3=15U%(5D))2D?_VP!#`0P-#1$/$2(3$R)',"@P1T='1T='1T='1T='1T='
M1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T?_P``1"`!^`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#U6BBBD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%4M8U*'2=+GO[DD1PKN('4^@_$T`2W=
MW!:1JT\@0,P5?5B>@`J4-7'>"1/KTDOB;4&):1FBM8OX8D!Y(]R>,^U2>*/$
M5Q8WGV.SVA@H+2$9(SV%*4E%79K1HSK3Y('6EJ@EO88)XX99`CRYV9Z,1VSZ
MUYO'XCUA'W?;G;GHV,5U>GW4/BK09K:[3:^-K[>,-V8>E9PJQF[(Z<3@*N'C
MS2U1TP-+7$>#/$-TVHW/A[6W!O;0D)(3S*!_7&#]*[;M6IPBT5SLGCCPW%(T
M;ZG&&5BK#:W!'X5JZ=JVGZI`9K"[BN$!P2AZ?44P+M%<Z?'7AI6*G5(P0<'Y
M6_PK1TO7-+U<,=-O8KC;]X*>1^%(#1HK+3Q#I4FLMI*7:F]4D&'!R,#/\JEU
M;6+#1X4FU*X6!';8I8'D^E`%^BJ>H:I9:;8&]O9UBMQC]X>G/2K$$T<\*2PN
M'CD4,K#H0>0:`)**J:GJ5GI5FUW?SK!"I`+-ZFF:5J]AK%LUQIMPL\2MM+*#
MP?3F@"]115+5=5L='M/M.HSK!"6"[B#U/T^E`%VBN<7QUX98X&JQ#/JK#^E:
M]QJ5G;:<U_+.HM57<91R,>O%`%RBJFFZE9ZI9K=V$PFA8D!P.N*H7_BS0=.N
M6M[O4H8Y5^\O)V_7%`&U15:QO[34;9;BQN$GB;HZ'(J#5=:T[1XXY-1NE@61
MMJ;@>30!H453U#4[/3;%KV]G$5NN,N0<<\#^=/FO[:#3VOY90MLL?F&3MMQG
M-`%FBN<_X3OPSC/]J1X_W&_PK0M_$&EW.E2ZG#=*]G%D/*`<#'6A`:=%<X/'
M?A@G_D*Q?7:W^%;-CJ-GJ,`FL;F.XC/\2'/_`.J@"U124M`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`E<!\89Y(]!LX48A);CY\=\*2*]`KG_&FA?V_P"'YK5/
M]>G[R$G^^.WX]*`(?AW+%-X+L/*Q\B%6]F!.:J>+/#UQ=W9O;(>8Q`#1]S[B
MN$\%^*KCPK?RV&H1N;9GVRI_%$V<$@?S%>R6=S;WMLES;2I-&XRKH<@TI14E
M9FU&M.C/F@>8IH.JNVT6,V?4K@?G7=>&]'_LBR97?=-*=S^@]A6W@5QGC?QM
M;:)#)9V3+-?L"!M((A]V_P`*B%&,'<Z<3CZN(CRO1'(:A<A?C%');,#_`*9'
M&<=\X5A^IKV$?=YKQ_X9Z!/J6MC6KK?Y-N^]6;)\V3GOWQU/OBO8?X?PK4X#
MQOP?#HLWB+6AKOV;R1NV&=@H!WG.*E\&".+XD2Q:%([Z;^\#8.5*8."?QP*A
M\&^'[#Q'XEU:'41(R0LS+L?;R7(KU'2-`TS0[=X]-M5BW#YGZLWU/4T`>3>!
MW\/KJ6H?\)%]G$17]WYW/.XYQ^%:7@JT27XB27.@1RKI4>_<[9P5QTY]^:K_
M``\T73];U/5(=2@$JK'E#D@J23R,5H^`KF;P]XQO/#MY(PCD8B(-T+#D$?5?
MZ4`%A_R6^?']]_\`T53?BY<2W>IVVGVX9Q;P/<2A?X1ZGZ`?K2V!_P"+WW'?
MYW_]%5;\/VQ\1>+/$M\S!H3$]HAZCD;1^@_6@#,\4ZO-J'@30+*+,LUTN7`Z
MDI\O\\_E7:_#J\:[\&61=MS1!HC^!X_3%<-\-=+GN_$;B]R8M,1T"-_"S$C`
M_4UL_#B[_LF;7]*NW"I8RF4,3T&2#_(?G0`SXCS-K/B72_#<#$%F#R8[9_P`
M)J'P-(?#?C:_\/7+%8IF)@W=R.5/XK_*LSP_;Z_XA\1WOB#2G@26.0A7N.0H
M(P`.#T6D\76GB/2-3L=>U:2UFF2151H!@`KR`>!UY%`'LE<5\6_^1/7U^U)_
M)JZG2;^/4M,MKV+[L\8<#.<9[5RWQ:_Y$Y?^OI/Y-0!Q5Q<>%G\!P0QQ*^M;
M``8T8,'SW.,'BN@@L;S3_@_>07Z/'(59EC?JJDC'^-48[GPD/AY''=+;-J/V
M<X$<8$V_)QSC/IUIVCRWDWPCU4W99HU)$+.225XSSZ9S0!9TC4I-*^#\EU`Q
M28L\:,#T+-C/ZU>\%>"M+N/#T5]JMN+NYO%WEG8_*#TQSU]ZSM.T^34O@T\,
M*EI$=I5`&2=K9_E6UX%\4Z8_ABVM[J\@MIK9/+9)9`I..XSVH`Q]'@/A/XE_
MV3;R.;&]7*(S9QD$C\01CZ&J'Q;O3=:[#9PY=;.#S),<[2QZG\`/SK0L[A?$
MWQ66^M!NL[&/'FCH<`X/XDT>%K"'Q+K'B/5)OGBFW6\1//#=Q^`7\Z`*'C36
M)M5\*Z!:6^6>XA$TB+R25&/YYKH;>]-]\'9I'^\ED\9_X""!_(5S?PRTEM0U
MN6XO2SQ:;&8D1N1EBPQ^&6JSH-R8_!GBK1I,@V0D*_0Y'\Q^M`%?P3=>#X="
M*:^MM]K\UCF6-F.WC'(%=AJZZ9_PKK4)=$6-;22%F0QJ5!.<$\_2N9\!3^%4
M\.XUM=.-SYS'_2(U9MO&.H-=1KD^FS_#[4_[':`VJ0LJ^2`$![@8^M`&#\.O
M#ND:OX1=]0L8YI#.Z^8>&`XZ$5E3VDO@;Q]9I932&SN67Y"W56.T@^N*U?AS
MXBTG2?";Q7]]%#()W?83\Q'':LJ2[N/'7CRTEM('6SM67YR/NJ#G)],D4`>N
MBG4@Z4M(`HHHH`****`$W#UHR*\WA\4:O$?]>LG^^H_I5R/QG?K_`*R&!OP(
MK'V\#T'EM=;69WF117%IXW?/[RQ4_1__`*U6X?&MFW$EO,A_`BFJL'U,G@JZ
M^R=31FL`>+M+/5I1_P``-21>*=*D.!*P_P!Y<57/'N9/#UEO%FWD49%48=6T
M^8#9=PY]"XJPMQ`WW94/T:KNF9N,ENB>DS30ZGH0?I1D$YHT)'4M-SS2T`+1
M244`+1244@%HI**8"T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2'I2T4`<+XY\
M"1ZSNU#3=L-Z!\RG@2_7W]ZX;PGJVOZ#J_V*")RH/[VVG)"H.['T^M>XM7DO
MQ1U83:U_9=G%&)`BK/(J_O)#U"$^G(./6F!-XG^)<DJ/::&OE@Y5KD]?^`C^
MIK%\)^#;_P`2W7VN\:2*T+;GF?.Z7_=SU^M96JZ%J/AVYM7U*W3$F)$!.Y6`
M['_"O=-!O+?4-&M+RUC$<4L0*H!@+VQCVH`L6%E;Z?9QVMI"L4,8PJJ,8JP:
M6B@#.T[0]-TRYEN+&TC@DF_UC+U;G-:!&:6B@#,TS0=,TJ622PM(X'D&'*?Q
M43:#IEQJB:E-9QM=H05E(^8$=*TZ*`,P:!I@U-]2%G&+Q\[I>YR,?RJ32]'L
M=(C>/3K:.W61MS!.Y]:OT4`4K/3+2QFGEM;=(GN&WRLHP6/J:KOX?TN2>ZF:
MSC\R[79.W3S!QP?R%:M%`%/2],L])MC;V%ND$18L50<$^M&I:;::I;?9[^V2
M>+<&VN,C([U<HH`JZ?8V^G6JVUG$(H4SM0=!3=3TRSU6V%M?P+/"&#;&Z9'?
M]:N44`8*>#/#B,&&DVV1ZKFM*;3+*;3S8/;1_92NTQ!<+CTXJY10!3L-.M=-
MM!:V,*PPKDA%Z#/6L+4?`'A_4;LW,MH8I&.6\ER@;\!74T4`9NF:)8:5:&UL
M+9(8V'SXZM]3WI^EZ18:3;M!IUJEO$S;F51U/2K]%`%*PTRSTXS?8K:.'SGW
MR;!C<WJ:@'A_2U>[=;*,->@K<$<>8#US6I10!S__``A7AO'&DP?K5Z#0M-@T
MV33HK2-+23.Z(=#GK_*M*B@#`7P5X<4@_P!DVY(]16K8Z?9Z?'Y=E;16Z=Q&
MH7-6J*`"BBBD`4444`%%%%`'CM+7>/X+TYONO.GT8?X53G\$#_EWO"/:1<UP
M>PFCZ2.8T7N[''T"NCD\&:BI.R6%_P`2/Z55D\+:M'_R[A_]U@:ETIKH;1Q=
M"7VC'I:NR:-J</W[&<#V7/\`*JLD,L38DC=#_M*14N,EN:JI"6S&]J4$C[I(
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MOH_N74O_`'UFK2:_J2#_`%^[ZJ*I8B)D\OJ+9H[GGUHR:XQ?$NH#J8V^JU,O
MBF\'WHHF_,4_;P(>!K(Z[)HKF(_%+9_>6P_X"U6$\46Q^]#*/RJO:P[F;PM9
M?9-^BL,>);(]4E'X"IH]?L&/+LOU6GSQ[D.A57V6:V:*H+K.GMTN`/J"*D75
M+%O^7N+_`+ZI\R[D>SFMT7**@2[MI/N3QM]&%2!U/1@?QIW)LT/HI-P]11D>
MM,0M%)D49H`6BDS1D4`+129I:`"BBDH`6BDI:`"BDHH`6BDR*`<T`+1129H`
M6BDHH`6BDS10`&N`_P"$>\GXJ"_NX]]O<*9(68?+Y@7&/KP37?U'+#',,2(K
M`'(R.AH`YKXC6L5UX1N$9"\H=/(`&6+D@`#ZY-:7A/3Y=*\-65C/CS8H_G`[
M$DDC]:TFA1I$=E#%>A/.*EI@+1124@%HI,T9I@+129HS0`M%)FC-`"T4F:*`
M%HHI*`%HI,T47`6BDHS0`M%)D44`+1244`+1249H`6BDS1F@!:*3-&1ZT`+1
M29%&12`6BF[AZBHIKNV@&9IXT'^TX%(:3>Q/168^OZ2AP;^`_1L_RHI<R[EJ
ME4?V7]QIT4451F)1BEI*`$*BF/"CC#JK#T(S4E&*`*<FF6,A^>TA/_`!52;P
MWI4N<VP7_<)7^5:^*,4N6+Z%JI..S.;?P=8,?DEG7VW`U6D\%ISY5X1_O)FN
MMQ1BH=*#Z&RQ==?:.&E\'WRG]U-"X]R15:3PQJB=(5?_`'7%>A8%&!4.A!FR
MS"LMSS5]'U&,X:SE_!<U"]G=1#]Y;2KCU0UZAM%(44C!`(]ZEX==&:K,Y]4>
M5#K2]Z].DL;208DMHF^J"JTFB:;)]ZSB_`8J7AWT9JLSCUB>>4M=Q+X8TV3[
ML;1_[K&JK^$;4_<N95^H!J70F:K,:3WN<D*45TK^$6'^KNP?8I_]>JS^%[]?
MN/$_XXJ'2GV-%C*+^T8HI:T6T#4EZ0!O]UA4,FEW\?#VDOX+G^52X270T5:G
M+:2*HI14AMIT^_#(OU0BF8(X((^M39E*2>PHI1UIHIPZT`/%+312TQ,<*<*:
M*<*!6'9]J>K,.C$?0U'3J=R6EU)EGE'25Q_P(U(MW<CI/(/^!FJPIPI\S,W3
MCV+::A=KTN'_`!-3IJUZ!_K<_516>*<*I2EW(=&#Z&DNLW>.=A_"I%UNX[I&
M:RQ2BJ522ZD/#T_Y3676YAUB0_2I!KC=X1^!K&!I<T_:2)>&I=C;&N)_%"WY
MT\:W!CF.0?E6":0FJ]K(CZI39T`UNU[B0?A2C6[/NS#_`(":YTFFFE[:0?4Z
M9TPUFR/67'U4TX:K8G_ENM<KS32.:?MV+ZE!]6==_:5E_P`_"?G2C4;,]+B/
M\ZXXCFFFCZP^P?4(]SM?MUK_`,_,?_?0IPNK4]+B,_\``Q7#GZ"FT_K#["^H
M+^8[P3PGI*A_X$*<)$/\8_.N`[T%F!X8TOK'D+ZAVD>@;@>XHR/6O/\`S9!T
MD<?1C1]JN!TN)1_P,T_K"[!_9[_F/0,^]+GWKS_[;=_\_4W_`'\-'V^\'_+U
M-_WV:/K"[!_9TOYCT#-)FO/_`.T+WM=3?]]FC^TKX=+J7_OHT_K"["_LZ?<]
M!S[49]J\]_M2_P#^?N7_`+ZH_M74/^?R7_OJCZQ'L']G3[H]"S[49KSS^UM1
M_P"?R7_OJD_M?4?^?R7_`+ZI_6(]@_LZIW1Z'FC/L:\[.KZC_P`_DO\`WU2'
M6-2Q_P`?DOYTOK,>P?V;4[H]&S1GVKSC^V-2_P"?R7\Z0ZQJ7_/[-_WU1]8C
MV'_9M3NCTC/M29KS?^U]2_Y_9O\`OJFG5]1_Y_9O^^J/K$>P_P"S:G='I>:3
M\:\S.K:C_P`_DW_?9I#JFH?\_L__`'V:7UA=A_V9/^8]-S03BO+SJ=_WO)_^
M_AIIU"];K>7'_?P_XT?65V*_LN?\QZCN7U%(TL8'S.H_&O*WNKA_O7$I^KFH
MV=R.78_4T?6?(I95+^8]4:ZM5^]/$/\`@8J-M2L%ZWD`_P"V@KRTDGK12^LO
ML4LJ761Z>VL::HYOH/\`OL5&=>TH=;V+_OJO,B>:/TI?67V*650_F9Z1)XET
ME/\`E[5OH":@;Q?I*])7;Z1FO/2:*7UB1HLKI=6SO6\::</NQS-_P&H)/&]L
M/]7:2M]2!7$T=JGV\S19;01U<OCB8Y\JR4?[SY_I5=O&E^?NPPC\S_6N;I*E
MU9OJ:K`8=?9-V7Q=JTGW7CC_`-U/\:I2Z[JLI^:_F^BG;_*L^BIYY=6:1PU&
M.T43O>W<G^LN9F^LA-0,Q8_,2WU-%(>M)MLVC"*V0E%+14V*/9:***]4^*"B
MBB@`HHHH`****`"BBB@`HHHH`****`"DI:*`$HQ2T4`-Q013J*+@-`I2*6BB
MX#<#TJ-[>&08>)6^JBIJ*`3:*+Z38/UM(OP6H'T'3V_Y8;?]TFM6DJ>6/8M5
M)K9F%)X9MF.4DD7VSFH6\+@?<N&_%<UT=+4^SAV-%B:JZG+MX:N!]V9&_#%0
M/H%^O1%?Z-77TE2Z,#18RKU.-;1[]1_Q[$_0@U$UC=Q_>MY!_P`!KM\4A4'K
MS4^PCW+6.GU1PQBD7AHW'U4TF"!R"/K7<%>>`*:T$3\/&K?5:3P_9EK']T<4
M"*4&NN;3;-NMN@^@Q43:/8L?]5CZ$TO8/N4L;'L<QFEKHGT.U;H77Z-G^=0-
MH"_P3L/J*7L9%K&4WN8M+6L=`?\`AG'_`'S4;Z'<C[LB-4^SEV+6)I/J9M)F
MKC:3>K_RR#?1A4;:=>+UMW_+-+DEV+5:F]FBL:3-2M:W*_>@D'_`343(XZHP
M_P"`FI:9:G%[,::::4Y'7BFDU):$)I":4TTB@H0FDI332:!H0TE+334E(0TA
MI:0T#&FD-*>E(>E`QM)2TE`Q*0T'I0:!C3TI*4TE(I"&FGI2FD/2F,*::6DH
M&!IIIQIIZ4AB4E%%,8E)2T=Z!B4E*>M)0,*2EI*`$[T444@$-%!HIC"D/2EI
M#TH&A*#10:`84444"#M24O:DH&%%%%`'LM%%%>H?%!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`"44M%`"48I:*`$HQ2T4`)BC%+10`FT48I:*`$QGK3?+4]5%/HH`C:")NL:G
M\*B?3[1_OV\9_P"`U9HI-)C4FMF9[:+8-U@_(FHVT&P/1'7Z,:U*2DX1[%JK
M-;,Q7\.6K?=>1?Q%5W\,C^"Y(^JUT5)BI]G#L6L1574YEO#4W\-RA^JXJ-O#
M5W_#)$?Q/^%=5BC%+V,&6L9674XV3P_J"]$1OHU0/H^HIUM7/T(-=UBDQ2^K
MQ-%CZJWL<"VFWPZVDOX*34+VMRGW[>5?JAKT3`HV@]JEX9=S19C/L>:'(/((
MIOYUZ88U(Y4'\*C-K;MUAC/U45+P_F6LQ[Q/-Z;7HLFFV;_>MHS_`,!J!]"T
MU_O6B?@2*3P\NY:S*'6+.`-)7=MX9TMND++]'-1/X5TX_=\U?HW^-3]7D:+,
M:7F<0:;79OX1L_X9YA]<'^E5W\'`_<NS^*5+H3-%CZ/<Y,]:2NF;P=<Y^6ZC
M/U6HV\'WP^[/"?S%+V4^QHL;0?VCG*0]*WV\(ZD.C0'_`($?\*KR>&-53GR%
M?_=<4O9S[%K%47]HQZ2M)]!U5>ME(?H,U"^E:BIP;*<?\`-3R2[&JK4WM)%*
MDJTVGWJ_>M9A_P``-1-;7"]8)!_P`T<K[%JI![,B/2DIS*RCYE(^HIF:5F6F
MNXM(:*3K0.X444G:D`4444QA1124#0E%%%(`HHHIA8.U)2]J2D`4444`>RT4
M45ZMCXH****+`%%%%%@"BBBBP!11118`HHHHL`44446`****+`%%%%%@"BBB
MBP!11118`HHHHL`44446`****+`%%%%%@"BBBBP!11118`HHHHL`44446`**
M**+`%%%%%@"BBBBP!11118`HHHHL`44446`****`"BBB@`HHHH`****+`%%%
M%%@"BBBBP"44M%%@$HI:*+`)12T4`)@4FVG44P&[?I3=H[@?E4E)B@",PQM]
MY%/U%,:SMFX:",_\!%3XHI60[ON4VTNP;[UI"?J@J)M$TMOO6,'_`'R*T<4;
M0:7*NQ2J36S,A_#>D/\`\NB#Z$C^M0MX2T@_\L7'T<UN[11BER1[%*O57VF<
MZW@[2ST\X?\``Z8?!>G'I)./^!#_``KI:*/9Q[%K%5E]IG+/X(M"/ENIA^7^
M%0/X&7^"_(_WDS_6NPP*,5/L8=BUC:Z^T<1)X&N/X+Z,_6,C^M0MX)U`?=N8
M#]<BN]P*,4O8P+_M#$=SSYO!FIK_`,M(#]&/^%1GPAJPZ+$?H]>BX%&.*7L(
M%+,:_D>;-X5U<#_CW4_1Q4+>&M87_ER<_1@?ZUZ?@48%)X>/<M9I671'E3:)
8JJG!T^X_!,T5ZK@44OJT>Y?]JU>R/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
